Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 17, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 1,200,000 ordinary shares of 25 pence each.
- Purchase Price: 1,193.00 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.14% of total voting rights).
- Shares in Issue: 5,187,661,593 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of the company's share capital through the cancellation of 1,200,000 shares purchased on December 17, 2008. This action was executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008. Consequently, the number of shares in issue was updated to 5,187,661,593.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total cost of the buyback transaction (1,200,000 shares at 1,193.00 pence).
- Confirm the updated total voting rights denominator (5,187,661,593 shares) for regulatory disclosure calculations.
- Note that the repurchased shares were cancelled rather than held indefinitely in treasury, though the company continues to hold a significant treasury position (9.14% of voting rights).